Clonidine and botulinum toxin: A tale of two treatments

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 5, 2014, Pages 852-853

  Wald, Arnold ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CLONIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

BIOETHICS; CLINICAL PRACTICE; COMPLIANCE (PHYSICAL); DOCTOR PATIENT RELATION; EDITORIAL; FEEDBACK SYSTEM; HUMAN; INFORMED CONSENT; IRRITABLE COLON; PATIENT SATISFACTION; PLACEBO EFFECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH EMPTYING; STOMACH PARESIS; URGE INCONTINENCE; FECAL INCONTINENCE; FEMALE;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; CLONIDINE; FECAL INCONTINENCE; FEMALE; HUMANS;

EID: 84898827758     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.022     Document Type: Editorial

References (14)

1. Bharucha A.E., Zinsmeister A.R., Schleck C.D., et al. Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterology 2010, 139:1559-1566.
2. Bharucha A.E., Camilleri M., Zinsmeister A.R., et al. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol Gastrointest Liver Physiol 1997, 273:G997-G1006.
3. Camilleri M., Kim D.-Y., McKinzie S., et al. Arandomized controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003, 1:111-121.
4. Bharucha A.E., Seide B.M., Zinsmeister A.R. The effects of clonidine on symptoms and anorectal sensorimotor function in women with fecal incontinence. Aliment Pharmacol Ther 2010, 32:681-688.
5. Bharucha A.E., Fletcher J.G., Camilleri M., et al. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol 2014, 12:843-851.
6. Whitehead W.E., Corazziari E., Prizont R., et al. Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. Gut 1999, 45(Suppl 2):II78-II79.
7. Finniss D.G., Kaptchuk T.J., Miller F., et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 375:686-695.
8. Ford A.C., Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010, 32:144-158.
9. Norton C., Chelvanayagam S., Wilson-Barnett J., et al. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology 2003, 125:1320-1329.
10. Miller L.S., Szych G.A., Kantor S.B., et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002, 97:1653-1660.
11. Bromer M.Q., Friedenberg F., Miller L.S., et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005, 61:833-839.
12. Friedenberg F.K., Palit A., Parkman H.P., et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008, 103:416-423.
13. Arts J., Holvoet L., Caenepeel P., et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007, 26:1251-1258.
14. Camilleri M., Parkman H.P., Shafi M.A., et al. American College of Gastroenterology Clinical Guideline: management of gastroparesis. Am J Gastroenterol 2013, 10:18-37.